GO
Loading...

Big move for PTC Therapeutics

Friday, 23 May 2014 | 2:40 PM ET

PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.